Haleon

The Dysmenorrhea Treatment Market, valued at USD 7.16 billion in 2023, is projected to grow to USD 13.09 billion by 2030, driven by increasing prevalence of menstrual disorders and advancements in treatment options. Growth factors include heightened awareness, development of personalized medicine, and acceptance of NSAIDs and hormonal therapies. Challenges include side effects of treatments, lack of awareness in developing regions, and societal stigmas. The market is competitive, with key players focusing on innovation and geographic expansion.

Pfizer Inc. to hold investor call for 2025 financial guidance. Goldman Sachs forecasts $64.9B revenue, $3.13 EPS, above consensus. 2024 EPS boosted by one-time items not recurring in 2025. Expects growth from market expansion, share gains, despite IRA Part D redesign impact. PFE stock down 0.39% at $25.48.

Centrum launches Joint & Mobility Capsule with UC-II and vitamin K2 to support cartilage repair and improve joint mobility in India, addressing a growing concern for bone and joint health.

Pfizer is considering divesting its hospital drugs unit, focusing on antibiotics and sterile injectables, amid pressure from activist investor Starboard Value. The unit, established after Pfizer's $17bn acquisition of Hospira in 2015, generates EBITDA nearing $500m. Goldman Sachs is soliciting interest from potential buyers, though the sale is not certain.

Sanofi plans to divest its consumer health unit, Opella, to focus on high-impact areas like oncology and immunology. A $17.4 billion deal with Clayton Dubilier & Rice for a 50% stake in Opella aligns with this strategy. Sanofi is investing in innovative therapies, including radioligand therapy and gene regulation, to strengthen its biopharma portfolio and address the patent cliff challenge.

Dopamine agonists, once first-line for restless legs syndrome (RLS), are no longer recommended due to long-term complications like augmentation. New AASM guidelines, led by John Winkelman, MD, PhD, recommend alternatives like alpha-2-delta calcium channel ligands and addressing iron deficiency.